Endocrine Flashcards
biguanide
metformin
sulfonylureas
glimepiride
glipizide
glyburide
thiazolidinediones
rosiglitazone
pioglitazone
DDP-4 inhibitors
sitagliptin
saxagliptin
linagliptin
alogliptin
GLP-1 receptor agonists
exenatide
liraglutide
dulaglutide
albiglutide
SGLT-2 inhibitors
dapagliflozin
canagliflozin
empagliflozin
alpha-glucosidase inhibitor
acarbose
amylin analog
pramlintide
meglitinides
nateglinide
repaglinide
non-insulin drugs for diabetes that cause weight gain
sulfonylureas
thiazolidinoediones
non-insulin drugs for diabetes that cause weight loss
GLP-1 receptor agonists
SGLT-2 inhibitors
amylin analog
meglitinides
non-insulin drugs for diabetes that cause hypoglycemia
sulfonylureas
amylin analog
meglitinides
non-insulin drugs for diabetes with SE UTIs and major mycotic infections
SGLT-2 inhibitors
non-insulin drugs for diabetes that may cause edema and worsen CHF
thiazolidinediones
non-insulin drugs for diabetes that you should not give to renal diseased patients
metformin sulfonylureas DPP-4 inhibitors GLP-1 receptor SGLT-2 inhibitors meglitinides
MOA metformin
decreases hepatic gluconeogenesis
improves insulin sensitivity (improves glucose uptake in tissues)
MOA sulfonylureas
inhibits potassium-ATP channels, increasing insulin release
*requires functioning pancreas
MOA thiazolidinediones
activate PPARgamma, improving tissue uptake of glucose and increased insuline sensitivity
MOA DPP-4 inhibitors
improve glucose-responsive insulin release
modest effect on gastric emptying
DDP-4 breaks down GLP-1, so inhibit that to increase GLP-1 levels
MOA GLP-1 receptor agonists
decreases glucagon secretion
improves glucose-responsive insulin release
delay gastric emptying
improve satiety
MOA SGLT-2 inhibitors
block reabsorption of glucose in renal tubule
MOA alpha-glucosidase inhibitor
blocks absorption of carbohydrates in the intestine
MOA amylin analog
augments insulin release
suppression glucagon
improves satiety
MOA meglitinides
inhibits potassium-ATP channel, increasing insulin release
1/2 strength SFUs
